These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Synthesis and biological evaluation of novel quinazoline-sulfonamides as anti-cancer agents. Poudapally S; Battu S; Velatooru LR; Bethu MS; Janapala VR; Sharma S; Sen S; Pottabathini N; Iska VBR; Katangoor V Bioorg Med Chem Lett; 2017 May; 27(9):1923-1928. PubMed ID: 28351589 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, Cytotoxicity and Molecular Docking Studies of the 9-Substituted 5-Styryltetrazolo[1,5-c]quinazoline Derivatives. Mphahlele MJ; Gildenhuys S; Parbhoo N Molecules; 2017 Oct; 22(11):. PubMed ID: 29072619 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents. Alafeefy AM; Ashour AE J Enzyme Inhib Med Chem; 2012 Aug; 27(4):541-5. PubMed ID: 21851213 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel 6-chloro-quinazolin derivatives as potential antitumor agents. Luo H; Yang S; Cai Y; Peng Z; Liu T Eur J Med Chem; 2014 Sep; 84():746-52. PubMed ID: 25064351 [TBL] [Abstract][Full Text] [Related]
8. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo. Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358 [TBL] [Abstract][Full Text] [Related]
9. Design, One Pot Synthesis and Molecular Docking Studies of Substituted-1H-Pyrido[2,1-b] Quinazolines as Apoptosis-Inducing Anticancer Agents. Bathula R; Satla SR; Kyatham R; Gangarapu K Asian Pac J Cancer Prev; 2020 Feb; 21(2):411-421. PubMed ID: 32102519 [TBL] [Abstract][Full Text] [Related]
10. Synthesis, Molecular Docking Study and in vitro Anticancer Activity of Tetrazole Linked Benzochromene Derivatives. Gorle S; Maddila S; Maddila SN; Naicker K; Singh M; Singh P; Jonnalagadda SB Anticancer Agents Med Chem; 2017; 17(3):464-470. PubMed ID: 27357544 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, computational quantum chemical study, in silico ADMET and molecular docking analysis, in vitro biological evaluation of a novel sulfur heterocyclic thiophene derivative containing 1,2,3-triazole and pyridine moieties as a potential human topoisomerase IIα inhibiting anticancer agent. Murugavel S; Ravikumar C; Jaabil G; Alagusundaram P Comput Biol Chem; 2019 Apr; 79():73-82. PubMed ID: 30731361 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent. Noolvi MN; Patel HM; Bhardwaj V; Chauhan A Eur J Med Chem; 2011 Jun; 46(6):2327-46. PubMed ID: 21458891 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, molecular modeling and anti-cancer evaluation of a series of quinazoline derivatives. Khodair AI; Alsafi MA; Nafie MS Carbohydr Res; 2019 Dec; 486():107832. PubMed ID: 31622868 [TBL] [Abstract][Full Text] [Related]
14. Quinazoline-sulfonamides as potential antitumor agents: synthesis and biological testing. Alafeefy AM; Alqasoumi SI; Ashour AE; Alshebly MM J Enzyme Inhib Med Chem; 2013 Apr; 28(2):375-83. PubMed ID: 22468752 [TBL] [Abstract][Full Text] [Related]
15. Single crystal XRD, DFT investigations and molecular docking study of 2- ((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)amino)naphthalene-1,4-dione as a potential anti- cancer lead molecule. P R KR; Mary YS; Fernandez A; S AP; Mary YS; Thomas R Comput Biol Chem; 2019 Feb; 78():153-164. PubMed ID: 30530296 [TBL] [Abstract][Full Text] [Related]
16. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors. Tu Y; Wang C; Xu S; Lan Z; Li W; Han J; Zhou Y; Zheng P; Zhu W Bioorg Med Chem; 2017 Jun; 25(12):3148-3157. PubMed ID: 28428040 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors. OuYang Y; Zou W; Peng L; Yang Z; Tang Q; Chen M; Jia S; Zhang H; Lan Z; Zheng P; Zhu W Eur J Med Chem; 2018 Jun; 154():29-43. PubMed ID: 29775935 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors. Jin H; Wu BX; Zheng Q; Hu CH; Tang XZ; Zhang W; Rao GW Future Med Chem; 2021 Apr; 13(7):601-612. PubMed ID: 33685233 [No Abstract] [Full Text] [Related]
20. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors. Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]